ANTHEM Anthem Biosciences Q3 FY26 results (Oct–Dec 2025) and concall
Anthem Biosciences delivered a strong 9M FY26 performance with consolidated revenue of ₹1,513 crore and a robust EBITDA margin of 41.5%, driven by backward integration and cost efficiencies. While Q3 revenue was impacted by a high base and global destocking, management remains optimistic for a strong Q4 and maintains full-year revenue growth guidance of 15-16% and margin guidance of 20%+. The company is actively expanding capacity and advancing its pipeline in peptides and biosimilars, positioning for future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 16.3%, net profit down 12.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 525 | 498 | 479 | 538 | 552 +5% | 417 −16% |
| EBITDA | 201 | 167 | 198 | 195 | 226 +12% | 163 −2% |
| Net profit | 170 | 128 | 123 | 148 | 198 +16% | 112 −12% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
